Apomorphine produced more yawning in Sprague-Dawley rats than in F344 rats: a pharmacological study.
Apomorphine induced yawning in both Sprague-Dawley and F344 rats in the same dose range, but F344 rats emitted only about 1/4 as many yawns as did Sprague-Dawley rats. At higher doses, rats of both strains exhibited stereotypic behavior with a comparable intensity. Pretreatment with either SCH 23390 [R(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-7-o l] or pindolol increased apomorphine-induced yawning further in Sprague-Dawley rats, but had little effect on the low yawning score produced by apomorphine in F344 rats. The low yawning response to apomorphine in F344 rats is, therefore, not due to a high baseline dopaminergic or adrenergic activity. Apomorphine-induced yawning in F344 rats was increased after an acute injection of physostigmine, or 24 h after an injection of reserpine. It is postulated that a low baseline cholinergic activity in F344 rats may be responsible, in part, for their lower yawning response to dopaminergic receptor stimulation.
Tang
A H
AH
CNS Diseases Research, Upjohn Company, Kalamazoo, MI 49001, USA.
Himes
C S
CS
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001552:Benzazepines / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D007279:Injections, Subcutaneous; D008297:Male; D010277:Parasympathomimetics / Q000494:pharmacology; D010830:Physostigmine / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D017207:Rats, Sprague-Dawley; D012110:Reserpine / Q000494:pharmacology; D013045:Species Specificity; D013239:Stereotyped Behavior / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology; D015000:Yawning / Q000187:drug effects* / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D001552:Benzazepines; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D010277:Parasympathomimetics; D013565:Sympatholytics; D012110:Reserpine; D010830:Physostigmine; D010869:Pindolol; D001058:Apomorphine